AI-Powered Melanoma Research

Advanced melanoma pioneered the immunotherapy revolution. AI agents research combination checkpoint blockade, BRAF/MEK inhibition, adoptive cell therapy, and novel approaches.

Get a $99 personalized brief on Melanoma

14 specialist agents compile a 30–50 page brief from PubMed-indexed research, delivered in 48 hours. Refund + free re-brief if not useful.

Standard of Care

Nivolumab + ipilimumab (or relatlimab), BRAF/MEK inhibitors (dabrafenib/trametinib), pembrolizumab, TIL therapy (lifileucel).

Prevalence

~100,000 new melanoma diagnoses per year in the US. ~8,000 deaths.

Five-Year Survival

Stage IV: ~30% with immunotherapy (up from ~5% pre-2011).

Key Mutations

BRAF V600E/K
NRAS
NF1
KIT
PD-L1 expression

Key Pathways

pd-1-pd-l1
kras-mapk
ctla-4-signaling

Clinical Trial Focus

Neoadjuvant immunotherapy, mRNA personalized vaccines (mRNA-4157), LAG-3 combinations, oncolytic virus (T-VEC 2.0).